Company Insights

NBY customer relationships

Explore interactive graphBrowse insights index
NBY customer relationship map

NovaBay (NBY) — customer map after the Avenova divestiture and what it means for investors

NovaBay Pharmaceuticals operates and monetizes as a specialty consumer and professional eye‑care product company that historically combined direct‑to‑consumer sales with wholesale distribution into physicians and national pharmacy channels. Revenue came from Avenova branded products sold directly on Avenova.com and Amazon as well as through national wholesalers and pharmacy dispensing channels; the company has since monetized that franchise through asset sales and financing agreements. For investors, the commercial footprint is now a mix of legacy distribution relationships, a completed sale of the Avenova eyecare business, and newly announced capital transactions that reshape counterparty exposure. For more background on how we source and normalize relationship data, visit https://nullexposure.com/.

High‑level commercial picture: a pivot from product sales to balance‑sheet actions

NovaBay’s commercial model in FY2024 leaned on three channels: direct online sales to individual consumers, retail marketplaces, and national pharmaceutical wholesalers that supply pharmacies and physician offices. The company executed a strategic divestiture of the Avenova business in early 2025 and followed with financing arrangements in 2026 that alter its counterparty profile from distributors and retailers toward institutional investors. That pivot changes investor focus from recurring product revenue toward asset realization and financing counterparties. Learn more about how relationship mappings influence investment decisions at https://nullexposure.com/.

Relationship snapshots (each relationship from disclosed sources)

AmerisourceBergen Corporation

NovaBay reports that it made prescription Avenova Spray accessible nationwide through agreements with AmerisourceBergen alongside other major wholesalers, demonstrating a national wholesaler channel into retail pharmacies. Source: NovaBay FY2024 Form 10‑K.

McKesson Corporation

McKesson is listed alongside other national wholesale distributors that carried prescription Avenova Spray into retail pharmacies across the United States, underscoring broad pharmacy access. Source: NovaBay FY2024 Form 10‑K.

Cardinal Health

Cardinal Health is named as a partner that helped place prescription Avenova Spray in retail pharmacy outlets nationwide, confirming the company’s use of three major U.S. wholesalers. Source: NovaBay FY2024 Form 10‑K.

Amazon.com

NovaBay promoted Avenova Spray directly to consumers on Amazon.com and recognized significant direct‑to‑consumer revenue through that channel ($7.2M for Avenova Spray in 2024 across online channels), indicating a material retail marketplace presence. Source: NovaBay FY2024 Form 10‑K.

Avenova.com

The company promoted products directly through its owned e‑commerce site, Avenova.com, and reported that a large portion of sales in 2023–2024 derived from direct consumer channels, signaling continued reliance on owned direct channels before the divestiture. Source: NovaBay FY2024 Form 10‑K.

Walmart.com

NovaBay made Avenova branded products available on Walmart.com as part of its online retail strategy, reinforcing multi‑channel DTC and retail distribution prior to the asset sale. Source: NovaBay FY2024 Form 10‑K.

Chongqing Pioneer Pharma Holdings Limited

Chongqing Pioneer (Pioneer) distributed NeutroPhase in China and is also a NovaBay stockholder; NovaBay continued manufacture of wound care products under contractual obligations to this Chinese distribution partner following the wound care divestiture. This relationship is identified as a distributor and an APAC channel in company filings. Source: NovaBay FY2024 Form 10‑K.

PRN Physician Recommended Nutriceuticals, LLC

Multiple news outlets report NovaBay completed the sale of the Avenova eyecare business and related assets to PRN (effective Jan. 17, 2025) for $11.5 million, shifting the Avenova brand and associated revenue streams away from NovaBay. Source: VisionMonday (news report, March 2026) and related news coverage.

Acumen Health Holdings

Independent news coverage also referenced Acumen Health Holdings in connection with acquisition activity around the Avenova brand; press aggregators reported Acumen in transaction headlines tied to the broader Avenova sale and corporate actions. Source: Finviz news summary (March 2026).

R01 Fund

TradingView coverage of NovaBay’s 2026 corporate actions listed R01 Fund as a participant in a securities purchase agreement, signaling fresh institutional capital relationships that complement the company’s asset sale. Source: TradingView (news, 2026).

Sky Frontier Foundation

Sky Frontier Foundation is named in the same securities purchase agreement coverage as a purchaser/participant, representing one of several new financing counterparties disclosed in 2026 reporting. Source: TradingView (news, 2026).

Framework Ventures

Framework Ventures appears among the purchasers in the securities purchase agreement media coverage, marking a shift in counterparties toward investment funds rather than product distributors. Source: TradingView (news, 2026).

Tether Investments

Tether Investments joined the group of purchasers named in trading coverage of NovaBay’s securities purchase agreement, completing the list of new institutional counterparties disclosed in the financing announcement. Source: TradingView (news, 2026).

What the constraints tell investors about NovaBay’s operating model

  • Direct‑to‑consumer orientation: The company explicitly promoted Avenova on Amazon.com and Avenova.com and reported direct consumer sales that produced millions in annual revenue (Avenova Spray $7.2M in 2024), so individual consumers were a material end market prior to the divestiture. Source: NovaBay FY2024 Form 10‑K.
  • Wholesale pharmacy coverage across North America: Agreements with McKesson, Cardinal Health and AmerisourceBergen reflect a nationwide retail pharmacy penetration in the U.S. (company‑level signal from FY2024 10‑K).
  • APAC distribution concentrated with Pioneer: NovaBay relied on Chongqing Pioneer for distribution in China for NeutroPhase; company filings identify Pioneer as both a distributor and a stockholder, which signals concentration and strategic dependence in APAC distribution. Source: NovaBay FY2024 Form 10‑K.
  • Product criticality and termination events: The company characterizes its wound care revenue as having relied solely on distribution partners (NeutroPhase, PhaseOne), and the Phase One distribution relationship was terminated upon the wound care divestiture — a sign the company’s product portfolio and revenue concentration were materially altered by the divestiture. Source: NovaBay FY2024 Form 10‑K.
  • Spend band before sale: Online and retail channel sales for Avenova Spray put annual channel revenue in the $1M–$10M range, consistent with disclosed $7.2M for OTC online sales in 2024. Source: NovaBay FY2024 Form 10‑K.

Investment implications and recommended next steps

  • Commercial risk profile has shifted materially: With the sale of Avenova and the erosion of a product revenue base that relied on DTC and national wholesalers, NovaBay’s counterparty risk moves from retail and distributor counterparties to a small set of institutional investors and purchasers. Monitor funding terms and shareholder dilution from the securities purchase agreement.
  • Concentration in APAC distribution remains a governance flag: The relationship with Chongqing Pioneer is both strategic and cross‑owned; evaluate contractual protections and termination rights if you assess exposure to APAC wound‑care revenue streams.
  • Near‑term value drivers are balance‑sheet actions: With Avenova monetized, near‑term upside hinges on how sale proceeds are deployed (special dividend referenced in news coverage) and how new financing counterparties influence capital structure. For detailed relationship mapping and alerts on counterparty changes, visit https://nullexposure.com/.

Bold takeaway: NovaBay has transitioned from operating a retail and distributor‑heavy commercial model to managing asset realization and institutional financing counterparties; investors must reframe due diligence from product forecasts to counterparty, contractual and capital deployment scrutiny.

For deeper analysis of counterparty exposure across small‑cap healthcare names, and to track changes to NovaBay’s relationship map in real time, go to https://nullexposure.com/.